Case report: Combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease

Journal of Clinical Apheresis

Volumn 21, Issue 4, 2006, Pages 249-251

  Gonzalez Carro P ^a   Perez Roldan F ^a   García Escribano, O Roncero ^a   Lafuente, R ^a   Legaz Huidobro, M L ^a   Amigo Echenagusia A ^a  

^a HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; NATALIZUMAB; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; APHERESIS; ARTICLE; CASE REPORT; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GRANULOCYTE APHERESIS; HUMAN; IMMUNOTHERAPY; LEUKAPHERESIS; REMISSION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COMBINED MODALITY THERAPY; CROHN DISEASE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKAPHERESIS; MESALAMINE; PREDNISONE;

EID: 33845923188     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20093     Document Type: Article

References (16)

1. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, De Woody KL, Schaible TF, Rutgeerts PJ. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337: 1029-1035.
2. Hanauer SB, Feagan BJ, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohns Disease: the ACCENT 1 randomized trial. Lancet 2002;359: 1541-1549.
3. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004;350:876-885.
4. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatments strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-413.
5. Sartor RB. Episodic retreatment versus scheduled maintenance therapy of Crohn's disease with Infliximab: not so far apart. Gastroenterology 2004;126:598-601.
6. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Izuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001;16:1-9.
7. Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, Iwao Y, Ishi H, Hibi T. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or dependent ulcerative colitis. Inflamm Bowel Dis 2004;10:251-257.
8. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled pilot study. Clin Gastroenterol Hepatol 2003;1:28-35.
9. Domenech E, Hinojosa J, Esteve-Comas M, Gomollon F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA. Spanish Group for the Study of Crohn's disease and Ulcerative Colitis (GETECCU) Granulocyteapheresis in steroid dependent inflammatory bowel disease: a prospective open pilot study. Aliment Pharmacol Ther 2004;20:1347-1352.
10. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocyteapheresis for Crohns Disease: A report on seven refractory patients. Am J Gastroenterol 2003;98:511-512.
11. Lampinen M, Carlson M, Sangfelt P. IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci 2001;46:2004-2009.
12. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR+ monocytes are a major source of TNF. J Immunol 2002;168:3536-3542.
13. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-608.
14. Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7(1): 48-59.
15. Hanai H, Watanabe F, Yamada M, et al. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-1538.
16. Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002;47:1334-1341.